Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin

  1. Petra Emmerich
  2. Carolin Murawski
  3. Ronald von Possel
  4. Lisa Oestereich
  5. Sophie Duraffour
  6. Meike Pahlmann
  7. Nicole Struck
  8. Daniel Eibach
  9. Ralf Krumkamp
  10. John Amuasi
  11. Oumou Maiga-Ascofare
  12. Raphael Rakotozandrindrainy
  13. Danny Asogun
  14. Yemisi Ighodalo
  15. Jürgen May
  16. Egbert Tannich
  17. Christina Deschermeier
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Specific serological tests are mandatory for reliable SARS-CoV-2 seroprevalence studies but assay specificity may vary considerably between populations due to interference of immune responses to other pathogens. Here, we assess the false positive rates obtained with four commercially available IgG ELISAs in serum panels originating from three different African countries.

Article summary line

Several commercially available SARS-CoV-2 ELISAs show limited specificity when applied to serum panels of African origin

Related articles

Related articles are currently not available for this article.